IRVINE, Calif. — March 5, 2026 — Leads & Copy — Biomerica, Inc. (Nasdaq: BMRA) has received official registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ diagnostic test, enabling commercial sale in Great Britain.
The hp+detect™ diagnostic test detects Helicobacter pylori (H. pylori) bacteria and will be marketed to labs throughout the UK for the detection of H. pylori infection in patients. Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
H. pylori is one of the most prevalent bacterial infections worldwide, affecting an estimated 44% of the global population. In the United Kingdom, H. pylori infection remains a significant public health burden, and the availability of accurate, non-invasive diagnostic tools is critical to enabling timely clinical intervention and appropriate antibiotic therapy in an era of increasing antimicrobial resistance. The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat, underscoring the clinical need for accurate diagnostics. H. pylori infection is the strongest known risk factor for gastric cancer, which is the third most common cause of cancer-related death worldwide. The Biomerica hp+detect™ product detects H. pylori bacteria, which is estimated to infect 35% of the U.S. population and 45% of the population in Europe’s five largest countries. Physicians and medical centers will be able to use hp+detect™ to diagnose H. pylori infection and monitor efficacy of treatments used to eradicate the infection.
Zack Irani, CEO of Biomerica, said that receiving MHRA registration for hp+detect™ is a meaningful commercial milestone that expands their international reach into the United Kingdom, which represents an important addressable market given the high prevalence of H. pylori infection across Europe. Irani added that this registration reflects Biomerica’s ongoing commitment to delivering innovative diagnostic solutions to patients and clinicians worldwide.
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Source: Biomerica, Inc.
